Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

EGFR mutations induce the suppression of CD8+ T cell and anti-PD-1 resistance via ERK1/2-p90RSK-TGF-β axis in non-small cell lung cancer.

Journal of translational medicine - 14 Jul 2024

Huang Huayan, Zhu Xiaokuan, Yu Yongfeng, Li Ziming, Yang Yi, Xia Liliang, Lu Shun

Abstract excerpt

BACKGROUND: Non-small cell lung cancer (NSCLC) patients with EGFR mutations exhibit an unfavorable response to immune checkpoint inhibitor (ICI) monotherapy, and their tumor microenvironment (TME) is usually immunosuppressed. TGF-β plays an important role in immunosuppression; however, the effects of TGF-β on the TME and the efficacy of anti-PD-1 immunotherapy against EGFR-mutated tumors remain unclear. METHODS:...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to CD8-Positive T-Lymphocytes

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Drug Resistance, Neoplasm

Share to Immune Checkpoint Inhibitors

Share to MAP Kinase Signaling System

Share to Programmed Cell Death 1 Receptor

Share to Transforming Growth Factor beta

Share to Tumor Microenvironment

Source

Open in PubMed Open full text

Identifiers

PMID: 39004699
DOI: 10.1186/s12967-024-05456-5
PMCID: PMC11246587

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

EGFR mutations induce the suppression of CD8+ T cell and anti-PD-1 resistance via ERK1/2-p90RSK-TGF-β axis in non-small cell lung cancer.PMID 39004699Read ↗

TGF-β Inhibitor Potentiates Osimertinib-Induced Anti-Tumor Immunity in Egfr-Mutant Lung Cancer.Semantic proximity Read ↗

EGFR-Mutated Non-Small Cell Lung Cancer and Resistance to Immunotherapy: Role of the Tumor Microenvironment.Semantic proximity Read ↗

IL6 Mediates Suppression of T- and NK-cell Function in EMT-associated TKI-resistant EGFR-mutant NSCLC.Semantic proximity Read ↗

Transforming growth factor‐β signaling: Tumorigenesis and targeting for cancer therapySemantic proximity Read ↗

<p>Immunotherapy after EGFR‑TKI treatment in advanced non‑small cell lung cancer: Current status and future perspectives (Review)</p>.Semantic proximity Read ↗

Roles of TGF-β signaling pathway in tumor microenvirionment and cancer therapySemantic proximity Read ↗

TGF-Beta: a Master Switch in Tumor ImmunitySemantic proximity Read ↗

Elevated TGFβ1 Drives IL4I1⁺ Macrophage–Gal-9 Signaling to Shape Tumor-Specific CD8⁺ T- Cell States in COPD-Associated NSCLCSemantic proximity Read ↗

Molecular Pathways: Targeting the TGF-β Pathway for Cancer TherapySemantic proximity Read ↗

TGF-β signaling in cancerSemantic proximity Read ↗

Shaping the battlefield: EGFR and KRAS tumor mutations' role on the immune microenvironment and immunotherapy responses in lung cancer.Semantic proximity Read ↗

Immunosurveillance and Immunoediting of Lung Cancer: Current Perspectives and Challenges.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.